TP53 mutant: Gene Variant Detail - Cancer Knowledgebase (CKB)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05611931	Phase III	Selinexor	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)	Recruiting	USA \| TUR \| SVK \| ITA \| ISR \| IRL \| HUN \| GRC \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS	3
NCT06085729	Phase Ib/II	ADI-PEG 20 + Cabazitaxel + Carboplatin	Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)	Active, not recruiting	USA	0
NCT04190550	Phase I	Cytarabine + Idarubicin + KRT-232	Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT01357161	Phase II	Carboplatin Adavosertib Paclitaxel	A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)	Completed		0
NCT04592237	Phase II	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	Active, not recruiting	USA	0
NCT05748171	Phase II	Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin	A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL	Recruiting	SWE \| SVK \| POL \| NOR \| NLD \| ITA \| ISR \| HUN \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| BEL \| AUT	0
NCT06058793	Phase III	BI 907828	Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma	Active, not recruiting	USA \| GBR \| CAN \| BRA \| AUS \| ARG	1
NCT05624554	Phase III	Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab ARQ 531	A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)	Active, not recruiting	USA \| TUR \| ROU \| POL \| LTU \| HUN \| DNK \| BRA \| BGR \| AUS	11
NCT06511882	Phase II	Decitabine + Venetoclax Azacitidine + Venetoclax	Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD	Recruiting	USA	0
NCT03945721	Phase I	Niraparib	A Phase I Study of Niraparib Administered Concurrently with Postoperative RT in Triple Negative Breast Cancer Patients (UNITY)	Active, not recruiting	USA	0
NCT04010968	Phase II	Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab	Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC)	Active, not recruiting	FRA	0
NCT04169737	Phase II	Acalabrutinib + Obinutuzumab + Venetoclax	Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recruiting	USA	0
NCT04113616	Phase Ib/II	KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)	Terminated	USA \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	1
NCT04908228	Phase II	Ibrutinib + Obinutuzumab	Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL (FIGHT)	Recruiting	ITA	0
NCT06482684	Phase II	Ibrutinib Ibrutinib + Rituximab Bendamustine + Ibrutinib + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Brexucabtagene autoleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab	CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (CARMAN)	Recruiting	DEU	0
NCT06152809	Phase I	Aldesleukin + CIML-NK cells + Venetoclax	CIML NK Cells With Venetoclax for AML	Active, not recruiting	USA	0
NCT02299141	Phase I	Nintedanib	Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer	Completed	USA	0
NCT03732352	Phase II	Osimertinib	18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma	Completed	USA	0
NCT05008055	Phase II	Capivasertib	Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)	Completed	USA \| GBR \| FRA \| ESP \| DNK \| CAN	1
NCT03360721	Phase II	Abiraterone + Apalutamide + Prednisone	Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer	Active, not recruiting	USA	0
NCT01760525	Phase I	CGM097	A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors	Completed	USA \| FRA \| DEU \| CHE	1
NCT03449381	Phase I	BI 907828	This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)	Active, not recruiting	USA \| SWE \| POL \| ISR \| ESP \| DNK \| DEU \| CAN \| BEL	2
NCT06660368	Phase II	Cladribine + Cytarabine + Filgrastim + Mitoxantrone Cladribine + Cytarabine + Filgrastim + Mitoxantrone + Venetoclax	BCL2i CLAG-M in R/R Acute Myeloid Leukemia	Recruiting	USA	0
NCT04634877	Phase III	Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab	Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)	Active, not recruiting	USA \| TUR \| SWE \| POL \| NOR \| ITA \| ISR \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUT \| ARG	9
NCT02642042	Phase II	Docetaxel + Trametinib	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT06578624	Phase Ib/II	SA53-OS	Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors	Not yet recruiting	USA	0
NCT04783415	Phase II	Acalabrutinib + Ublituximab + Umbralisib	Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma	Active, not recruiting	USA	0
NCT03787602	Phase Ib/II	Avelumab + KRT-232 KRT-232	Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS	1
NCT03047993	Phase Ib/II	Azacitidine + Telaglenastat	Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome	Completed	USA	0
NCT03072043	Phase Ib/II	APR-246 + Azacitidine	Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms	Completed	USA	0
NCT03836261	Phase III	Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax	Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)	Active, not recruiting	USA \| TUR \| SWE \| SVK \| POL \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| AUT \| AUS \| ARG	6
NCT03913026	Phase II	ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa	UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia	Active, not recruiting	CAN	0
NCT04485260	Phase Ib/II	KRT-232 + Ruxolitinib	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib	Unknown status	USA \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BGR \| AUS	0
NCT02301156	Phase III	Ibrutinib + Ublituximab Ibrutinib	Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)	Completed	USA \| ISR	0
NCT04734990	Phase Ib/II	Azacitidine + Seclidemstat	Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	Recruiting	USA	0
NCT03613532	Phase I	Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Recruiting	USA	0
NCT04285567	Phase III	Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab	A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| AUS	0
NCT04388852	Phase I	DS-3201b + Ipilimumab	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Recruiting	USA	0
NCT04412629	Phase II	Cabozantinib	Cabozantinib in High Grade Neuroendocrine Neoplasms	Recruiting	USA	0
NCT04159155	Phase II	Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP)	Recruiting	CAN	0
NCT02193152	Phase I	Pazopanib	Pazopanib in Molecularly Selected Patients With Advanced NSCLC	Terminated	USA	0
NCT05495464	Phase I	Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab	A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma	Recruiting	USA	0
NCT03383575	Phase II	Azacitidine + Enasidenib Enasidenib	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome	Recruiting	USA	0
NCT04660045	Phase II	Acalabrutinib	Early Intervention With Acalabrutinib in Patients With High Risk CLL	Withdrawn	USA	0
NCT03668340	Phase II	Adavosertib	AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Active, not recruiting	USA	0
NCT05512377	Phase II	BI 907828	Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder	Active, not recruiting	USA \| GBR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS	7
NCT03462719	Phase III	Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax	A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)	Active, not recruiting	USA \| TUR \| SWE \| POL \| NLD \| ISR \| GBR \| FRA \| ESP \| DNK \| CZE \| CAN \| BEL	1
NCT04659616	Phase I	Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib	Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia	Recruiting	USA	0
NCT04214860	Phase I	APR-246 + Azacitidine + Venetoclax	APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies	Completed	USA	0
NCT01027416	Phase I	Tamoxifen	Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients	Completed	USA	0
NCT03567642	Phase I	Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib	A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers	Active, not recruiting	USA	0
NCT03781986	Phase Ib/II	Alrizomadlin	APG-115 in Salivary Gland Cancer Trial	Active, not recruiting	USA	0
NCT03063203	Phase II	Decitabine	Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia	Terminated	USA	0
NCT03365661	Phase II	Nogapendekin alfa inbakicept	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	Withdrawn	USA	0
NCT04435691	Phase Ib/II	Azacitidine + Hu5F9-G4 + Venetoclax	Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT05155709	Phase Ib/II	Azacitidine + Siremadlin + Venetoclax	A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.	Terminated	USA \| TUR \| ITA \| ISR \| HUN	2
NCT05275439	Phase I	Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154	Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML	Completed	USA \| GBR \| CAN	0
NCT05431582	Phase I	Bevacizumab + Pembrolizumab + ZN-c3 Bevacizumab + ZN-c3	Phase I Study of ZN-c3 and Bevacizumab +/- Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors	Withdrawn		0
NCT05396859	Phase I	Decitabine and Cedazuridine + Entrectinib	Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	Recruiting	USA	0
NCT02007044	Phase II	Ibrutinib Ibrutinib + Rituximab	Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Active, not recruiting	USA	0
NCT05218499	Phase II	BI 907828 Doxorubicin	Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma	Active, not recruiting	USA \| SWE \| NOR \| NLD \| ITA \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUS	5
NCT03204188	Phase II	Fludarabine + Ibrutinib + Pembrolizumab	Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Active, not recruiting	USA	0
NCT04708054	Phase II	Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax	Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS	Recruiting	USA	0
NCT03844815	Phase I	Decitabine + Venetoclax	Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT02042989	Phase I	Ixazomib + Vorinostat	MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies	Completed	USA	0
NCT04293094	Phase I	AMG 650	Study of AMG 650 in Adult Participants With Advanced Solid Tumors	Completed	USA \| ITA \| ESP \| CAN \| BEL \| AUS	1
NCT05180695	Phase Ib/II	Pazopanib + Siremadlin	HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)	Recruiting	FRA	0
NCT06738303	Phase II	lutetium Lu 177 vipivotide tetraxetan Cabazitaxel + Carboplatin	Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer (CATCH-177)	Not yet recruiting	USA	0
NCT06297629	Phase II	Decitabine and Cedazuridine	A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation	Withdrawn	USA	0
NCT03734198	Phase II	Daratumumab + Ibrutinib	Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with P53 Dysfunction (IDA53)	Active, not recruiting	FRA	0
NCT05622058	Phase I	ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin	A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer	Terminated	USA \| BGR	2
NCT01339871	Phase I	Vorinostat Pazopanib	Phase I Study of Pazopanib and Vorinostat	Completed	USA	0
NCT05027867	Phase II	KRT-232	KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer	Terminated	USA \| HUN \| FRA \| ESP \| DEU \| AUS	1
NCT03745716	Phase III	APR-246 + Azacitidine Azacitidine	APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)	Completed	USA \| FRA	0
NCT04419389	Phase Ib/II	Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax	APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)	Terminated	USA	0
NCT04402073	Phase II	Cisplatin + Lomustine + Vincristine Sulfate Cisplatin + Lomustine + Sonidegib + Vincristine Sulfate	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Active, not recruiting	NLD \| ITA \| FRA \| ESP \| DEU \| CHE \| AUT \| AUS	0
NCT03931291	Phase II	APR-246 + Azacitidine	APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant	Completed	USA	0
NCT05156268	Phase II	Olaparib + Pembrolizumab	A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma	Active, not recruiting	USA	0
NCT02433626	Phase I	COTI-2 Cisplatin + COTI-2	Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)	Unknown status	USA	0
NCT04510584	Phase II	Atezolizumab + Bevacizumab	Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer	Withdrawn	CAN	0
NCT04277442	Phase I	Decitabine + Nivolumab + Venetoclax	Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT02275039	Phase I	MVAp53 Gemcitabine	p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer	Completed	USA	0
NCT05405309	Phase Ib/II	Olaparib + RP-3500	RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL)	Terminated	USA	0
NCT06313437	Phase I	Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib	Revumenib in Combination With 7+3 + Midostaurin in AML	Recruiting	USA	0
NCT05554393	Phase II	Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax	Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)	Recruiting	USA \| CAN	1
NCT04493138	Phase Ib/II	Azacitidine + Quizartinib	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations	Recruiting	USA	0
NCT03661307	Phase Ib/II	Decitabine + Quizartinib + Venetoclax	Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Recruiting	USA	0
NCT04146038	Phase II	Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax	Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Completed	USA	0
NCT02432963	Phase I	MVAp53 + Pembrolizumab	Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy	Active, not recruiting	USA	0
NCT04722172	Phase II	Acalabrutinib + Obinutuzumab	A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL	Active, not recruiting	USA	0
NCT05332483	Phase I	Megestrol acetate	Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer (MA-EEC)	Terminated	CAN	0
NCT05376800	Phase I	BI 907828	A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma	Active, not recruiting	USA \| ESP \| BEL	0
NCT03128879	Phase II	Acalabrutinib + Venetoclax Ibrutinib + Venetoclax	Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL	Recruiting	USA	0
NCT02343172	Phase Ib/II	Ribociclib + Siremadlin	Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma	Completed	FRA \| ESP \| DEU \| CAN	2
NCT06107868	Phase I	Carboplatin + Paclitaxel + RP-6306	Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (GyneRep)	Active, not recruiting	CAN	0
NCT03932643	Phase I	ONC201	ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant	Active, not recruiting	USA	0
NCT03634228	Phase Ib/II	Cytarabine + Milademetan Cytarabine + Milademetan + Venetoclax	Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia	Terminated	USA	0
NCT02629809	Phase II	Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib	Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia	Active, not recruiting	USA	0
NCT06366347	Phase II	Pembrolizumab Abemaciclib + Letrozole	ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab	Recruiting	USA	0
NCT06136884	Phase I	AO-252	A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors	Recruiting	USA	0
NCT02098343	Phase Ib/II	Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin	p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	Completed	USA \| SWE \| NLD \| GBR \| FRA \| ESP \| DEU \| BEL	0
NCT04022876	Phase I	ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium	A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)	Terminated	USA \| POL \| ITA \| ESP \| DEU	2

Gene	TP53
Variant	mutant
Impact List	unknown
Protein Effect	unknown
Gene Variant Descriptions	TP53 mutant indicates an unspecified mutation within the TP53 gene.
Associated Drug Resistance
Category Variants Paths	TP53 mutant

TP53 mutant - Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting